Healthcare >> CEO Interviews >> December 13, 2004
M. CHRISTINE JACOBS is Chairman, Chief Executive Officer, and President
of Theragenics Corporation', based in Buford, Georgia. Theragenics_
manufactures and distributes TheraSeed', an FDA-licensed device
primarily used for the treatment of prostate cancer. TheraSeed has been
used to treat over 100,000 men with prostate cancer in over 800
hospitals throughout the United States. During Ms. Jacobs' tenure as
CEO, Theragenics' production capabilities have quadrupled in size. Under
her leadership, Theragenics executed agreements with the U.S. Department
of Energy (DOE) that grant the company access to unique DOE technology
for the production of isotopes and constructed a $30 million, one-of-a
kind facility in Oak Ridge, Tennessee, to house this technology. In
Georgia, she built and oversees the largest cyclotron facility in the
world and the largest production facility for the active medical isotope
Palladium-103. Research programs involving the treatment of vascular
disease and macular degeneration are underway. Prior to becoming CEO of
Theragenics_ in 1993, Ms. Jacobs held the positions of President and
Chief Operating Officer (1992), Vice President of Sales and Marketing
and Director of Marketing (1987-1992). Since Theragenics' stock began
trading on the NASDAQ market during 1986, she coordinated three of four
private stock placements. During April 1997, she completed a secondary
offering of 2.3 million shares raising $32.2 million. On August 6, 1998,
Ms. Jacobs became the first woman Chairman/CEO in the history of the New
York Stock Exchange to transfer from the NASDAQ to the NYSE, opening
trade by ringing the NYSE opening bell. Profile
of what the company is currently doing?
Ms. Jacobs: Established in 1981, Theragenics Corporation manufacturers,
markets
